BioSpace News Archive

Following to the previous information on Jan. 30th. in 2024, we are excited to share our latest development status.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced the issue of a new U.S. patent covering Talicia1 as an all-in-one fixed-dose combination of amoxicillin, omeprazole and rifabutin and its use for the treatment of helicobacter pylori infection.

At the 20th US Human Proteome Organization Congress 2024, Bruker Corporation announced progress in immunopeptidomics, glycoproteomics and other CCS-enabled 4D-proteomics workflows.

Novocure announced a late breaking abstract which reviews the results of an exploratory subgroup analysis of the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 clinical trial has been selected for presentation at the “Best Oral Session – Late Breaking Abstracts” on Sunday, March 10, 2024 at the European Society on Gynaecological Oncology 2024 Congress in Barcelona.

Can-Fite BioPharma Ltd. announced its VP of Business Development, Dr. Sari Fishman, will present data from the pancreatic and liver cancer programs during numerous partnering meetings at the BIO-Europe Spring 2024 in Barcelona, Spain, on Mar 18-27, 2024.

SciAps, a global leader in scientific instruments and technology solutions, is proud to launch the newest XRF technology in its product line, the groundbreaking PowerHouse X, a portable benchtop with an 80 kV X-ray tube, specifically built to measure heavy REEs terbium, dysprosium, holmium, erbium, and ytterbium in the field.

Calidi Biotherapeutics Inc. and City of Hope jointly announced that the CIRM has awarded Karen Aboody, M.D., City of Hope professor in the Department of Stem Cell Biology and Regenerative Medicine and Division of Neurosurgery, a $5.3 million grant to fund preclinical translational studies, product manufacturing, and clinical trial design using Calidi’s licensed oncolytic virotherapy product, CLD-101, in patients with chemo-resistant, metastatic ovarian cancer.

Legend Biotech Corporation, a global leader in cell therapy, reported its fourth quarter and full year 2023 unaudited financial results and key corporate highlights.

Redwire Corporation announced today that Redwire Chief Financial Officer Jonathan Baliff will present at the 36th Annual ROTH Conference on March 18, 2024 from 8:30-8:55 a.m. PT.

Verastem Oncology today announced multiple oral and poster presentations, including a late-breaking oral presentation of avutometinib and defactinib combination from the RAMP 201 Part A trial in heavily pretreated patients with low-grade serous ovarian cancer (LGSOC), at the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer, to be held on March 16-18 in San Diego, California.